Exact Sciences: Cologuard® revenue increased 168 percent to $266 million
166939
post-template-default,single,single-post,postid-166939,single-format-standard,bridge-core-1.0.5,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.2,vc_responsive
 

Exact Sciences: Cologuard® revenue increased 168 percent to $266 million

exact-sciences

Exact Sciences: Cologuard® revenue increased 168 percent to $266 million

MADISON, Wis., Feb. 22, 2018 — Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $266 million and completed approximately 571,000 Cologuard tests during the year ended Dec. 31, 2017. Full-year 2017 revenue and Cologuard test volume grew 168 percent and 134 percent from 2016, respectively.

Exact Sciences Corporation Logo (PRNewsfoto/EXACT SCIENCES CORP)

During the fourth quarter of 2017, the company generated revenue of $87.4 million and completed approximately 176,000 Cologuard tests. Fourth-quarter 2017 revenue and test volume grew 148 percent and 115 percent from the same period of 2016, respectively.

571,000 people were screened with Cologuard during 2017
– Fourth quarter revenue increased 148 percent to $87.4 million
– Gross margin increased 1,250 basis points to 73 percent during the fourth quarter
– Nearly 11,000 healthcare providers ordered their first Cologuard test during the fourth quarter, and approximately 102,000 have ordered since the test was launched

READ FULL RELEASE